Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
Efficacy of TAGRISSO® (osimertinib) in resectable EGFRm NSCLC
Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy -
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study | Future Oncology
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
Efficacy of TAGRISSO® (osimertinib) in resectable EGFRm NSCLC
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - Journal of Thoracic Oncology
Osimertinib in Advanced Lung Cancer with EGFR Mutations - National Cancer Institute
TAGRISSO® (osimertinib) | AURA3 Study
TAGRISSO® (osimertinib) | FLAURA
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - Journal of Thoracic Oncology
Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis | SpringerLink
Efficacy of TAGRISSO® (osimertinib) in resectable EGFRm NSCLC
TAGRISSO® (osimertinib) | AURA3 Study
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
